Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Filgrastim in amyotrophic lateral sclerosis
2014-002228-28Phase 2Terminated
- Sponsor
- University of Turin and City of Health and Science Hospital
- Start
- Jun 2014
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing Filgrastim with Placebo (2 arms). Primary endpoint: Modification of progression rates of total disability score. Started Jun 2014; status: terminated.
02
Drugs
filgrastim
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on 2014-002228-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002228-28.